The US FDA's work over the years to speed production of industry and stakeholder guidance may be curtailed by a White House directive requiring the Office of Management and Budget review all of them before they are released.
Agency guidance, in addition to proposed and final rules, will undergo OMB review to receive an economic impact determination, which could allow congressional review of the document. OMB reaffirmed the practice and set out the review system in an April 11
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?